Zoetis Inc. (NYSE:ZTS) Shares Sold by Fundsmith LLP

Fundsmith LLP reduced its position in Zoetis Inc. (NYSE:ZTS) by 1.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 227,329 shares of the company’s stock after selling 3,397 shares during the quarter. Fundsmith LLP’s holdings in Zoetis were worth $37,039,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC raised its holdings in Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares during the last quarter. Rakuten Securities Inc. increased its holdings in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the last quarter. Navigoe LLC acquired a new position in Zoetis during the fourth quarter worth $30,000. Murphy & Mullick Capital Management Corp purchased a new stake in Zoetis in the 4th quarter valued at $44,000. Finally, Asset Planning Inc purchased a new position in shares of Zoetis during the 4th quarter worth $58,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ZTS. Stifel Nicolaus cut their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Monday, April 14th. StockNews.com upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. Morgan Stanley cut their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Piper Sandler increased their price target on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Finally, UBS Group reduced their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Zoetis has a consensus rating of “Buy” and an average target price of $212.13.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the firm’s stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock valued at $312,254. 0.18% of the stock is currently owned by corporate insiders.

Zoetis Price Performance

Zoetis stock opened at $161.77 on Friday. The company’s 50 day moving average is $157.47 and its two-hundred day moving average is $166.42. The firm has a market cap of $72.18 billion, a PE ratio of 29.57, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.20 billion. During the same quarter in the previous year, the business posted $1.38 EPS. The firm’s revenue was up 1.4% on a year-over-year basis. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.